| Abraham Abernethy, | |
|
96 Campus Dr Ste 1, Scarborough, ME 04074-7164 | |
| (207) 885-9905 | |
| Not Available |
| Full Name | Abraham Abernethy |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 15 Years |
| Location | 96 Campus Dr Ste 1, Scarborough, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306071428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 20788 (New Hampshire) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD24065 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Memorial Hospital, The | North conway, NH | Hospital |
| Franklin Memorial Hospital | Farmington, ME | Hospital |
| Southern Maine Health Care | Biddeford, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maine Medical Partners | 9335043967 | 789 |
| Mainehealth | 7517860588 | 2067 |
| St Marys Regional Medical Center | 0042107120 | 203 |
| Memorial Hospital | 2365418993 | 86 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
Increased access to no-cost antiretroviral drugs has contributed to a 75% decrease in AIDS-related deaths in Malawi in the last four years, a senior government official said Monday, Reuters reports.
Now final-year design student Oscar Daws from Brunel University London has come up with a streamlined device which has been selected for a prestigious exhibition on London's South Bank and aims to vastly improve patients' self-management of the disease...
Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
› Verified 7 days ago
| Entity Name | St Marys Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447226584 PECOS PAC ID: 0042107120 Enrollment ID: O20040303000236 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
Increased access to no-cost antiretroviral drugs has contributed to a 75% decrease in AIDS-related deaths in Malawi in the last four years, a senior government official said Monday, Reuters reports.
Now final-year design student Oscar Daws from Brunel University London has come up with a streamlined device which has been selected for a prestigious exhibition on London's South Bank and aims to vastly improve patients' self-management of the disease...
Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104921535 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000274 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
Increased access to no-cost antiretroviral drugs has contributed to a 75% decrease in AIDS-related deaths in Malawi in the last four years, a senior government official said Monday, Reuters reports.
Now final-year design student Oscar Daws from Brunel University London has come up with a streamlined device which has been selected for a prestigious exhibition on London's South Bank and aims to vastly improve patients' self-management of the disease...
Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285738310 PECOS PAC ID: 9335043967 Enrollment ID: O20040525000396 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
Increased access to no-cost antiretroviral drugs has contributed to a 75% decrease in AIDS-related deaths in Malawi in the last four years, a senior government official said Monday, Reuters reports.
Now final-year design student Oscar Daws from Brunel University London has come up with a streamlined device which has been selected for a prestigious exhibition on London's South Bank and aims to vastly improve patients' self-management of the disease...
Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
› Verified 7 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
Increased access to no-cost antiretroviral drugs has contributed to a 75% decrease in AIDS-related deaths in Malawi in the last four years, a senior government official said Monday, Reuters reports.
Now final-year design student Oscar Daws from Brunel University London has come up with a streamlined device which has been selected for a prestigious exhibition on London's South Bank and aims to vastly improve patients' self-management of the disease...
Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abraham Abernethy, 96 Campus Dr Ste 1, Scarborough, ME 04074-7164 Ph: (207) 885-9905 | Abraham Abernethy, 96 Campus Dr Ste 1, Scarborough, ME 04074-7164 Ph: (207) 885-9905 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 million for the second quarter of 2009. Net income for the second quarter of 2010 was $2.9 million, or $0.10 per basic and fully diluted common share, compared to $2.5 million, or $0.09 per basic and fully diluted common share, for the second quarter of 2009.
Increased access to no-cost antiretroviral drugs has contributed to a 75% decrease in AIDS-related deaths in Malawi in the last four years, a senior government official said Monday, Reuters reports.
Now final-year design student Oscar Daws from Brunel University London has come up with a streamlined device which has been selected for a prestigious exhibition on London's South Bank and aims to vastly improve patients' self-management of the disease...
Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
› Verified 7 days ago
Dr. Mary C. Fahrenbach, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Drive, Suite 1, Scarborough, ME 04074 Phone: 207-885-9905 Fax: 207-396-5600 | |
Mark A Wrona, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 51 Us Route 1 Ste I, Scarborough, ME 04074 Phone: 207-303-3300 Fax: 207-250-2139 | |
Dr. Mylan C. Cohen, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 96 Campus Drive, Suite 1, Scarborough, ME 04074 Phone: 207-885-9905 Fax: 207-396-5600 | |
Mirle A Kellett, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Dr, Suite 1, Scarborough, ME 04074 Phone: 207-396-5611 | |
Dr. Warren D Alpern, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Dr, Suite 1, Scarborough, ME 04074 Phone: 207-396-5611 | |
Dr. Eleni Nicole Nackos, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Dr Unit 108, Scarborough, ME 04074 Phone: 207-303-3300 Fax: 207-250-2139 | |
Susan Miesfeldt, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Drive, Suite 110, Scarborough, ME 04074 Phone: 207-396-7678 Fax: 207-396-8766 |